Skip to main content
Michael Miller, MD, Cardiology, Fayetteville, NC

MichaelJMillerMD

Cardiology Fayetteville, NC

Adult Congenital Heart Disease, Cardiac Electrophysiology, Interventional Cardiology

Physician

Dr. Miller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Miller's full profile

Already have an account?

  • Office

    3637 Cape Center Dr
    Fayetteville, NC 28304
    Phone+1 910-491-1760
    Fax+1 910-491-1764

Summary

  • Dr. Michael Miller is a cardiologist based in Asheville NC, with subspecialties in adult peripheral and interventional cardiology. He completed his medical education at the University of Pittsburgh School of Medicine, followed by a residency and fellowship at Duke University Hospital. Dr. Miller has experience in valvular heart disease, cardiac catheterization, peripheral vascular disease, and cardiac critical care.

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Cardiovascular Disease, 1988 - 1991
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 1985 - 1988
  • University of Pittsburgh School of Medicine
    University of Pittsburgh School of MedicineClass of 1985

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 1987 - 2025
  • SC State Medical License
    SC State Medical License 1992 - 2015
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Heart/Stroke Recognition Program National Committee for Quality Assurance, 2010-2013

Press Mentions

  • Hemostemix Announces Three Additional Sites Enrolled in Phase II Clinical Trial
    Hemostemix Announces Three Additional Sites Enrolled in Phase II Clinical TrialNovember 7th, 2018